| 卢春霞,邢燕飞,崔宝生,陈坤燕.埃克替尼联合恩度对EGFR突变阳性肺腺癌患者疗效及预后的影响.[J].中南医学科学杂志.,2024,(3):449-452. |
| 埃克替尼联合恩度对EGFR突变阳性肺腺癌患者疗效及预后的影响 |
| Effects of Ectinib combined with Endu on the efficacy and prognosis of EGFR-mutation-positive lung adenocarcinoma patients |
| 投稿时间：2023-12-10 修订日期：2024-04-02 |
| DOI：10.15972/j.cnki.43-1509/r.2024.03.034 |
| 中文关键词: EGFR突变 肺腺癌 埃克替尼 恩度 肿瘤标记物 [ |
| 英文关键词:EGFR mutation lung adenocarcinoma Ectinib Endu tumor marker |
| 基金项目:南通市卫生健康科研基金(QNZ2022086) |
|
| 摘要点击次数: 82 |
| 全文下载次数: 65 |
| 中文摘要: |
| 目的观察埃克替尼联合恩度对表皮生长因子受体(EGFR)突变阳性肺腺癌患者的临床效果及预后的影响。 方法回顾性选取124例晚期EGFR突变阳性肺腺癌患者为研究对象,根据治疗方案分为埃克替尼组(单用埃克替尼)及恩度联合组(埃克替尼联合恩度)。比较两组患者治疗前和治疗4周期时肿瘤标记物和免疫功能指标水平；比较两组近期疗效；观察两组治疗期间不良反应发生情况；采用Kaplan-Meier法比较两组患者远期疗效无进展生存时间(PFS)及总生存时间(OS)生存曲线。 结果治疗4周期时,两组患者肿瘤指标及CD8＋水平均较治疗前明显降低(P＜0.05),且恩度联合组低于埃克替尼组(P＜0.05)；两组CD3＋、CD4＋、CD4＋/CD8＋水平均较治疗前升高(P＜0.05),且恩度联合组高于埃克替尼组(P＜0.05)。恩度联合组OS长于埃克替尼组(P＜0.05)。两组患者近期疗效、PFS、不良反应比较,差异均无显著性(P＞0.05)。 结论埃克替尼联合恩度的二线治疗方案有助于提高EGFR突变阳性肺腺癌患者的总生存期,且安全性良好。 |
| 英文摘要: |
| AimTo observe the clinical efficacy and prognosis of Ectinib combined with Endu in the treatment of epidermal growth factor receptor (EGFR) mutation-positive lung adenocarcinoma. Methods124 patients with advanced EGFR-mutation-positive lung adenocarcinoma were retrospectively selected as the study subjects, and were divided into Ectinib group (Ectinib alone) and Endu combined group (Ectinib combined with Endu) according to the treatment plan of the patients. The levels of tumor markers and immune function indexes were compared between the two groups before treatment and after 4 cycles of treatment. The short-term curative effects of the two groups were evaluated. The occurrence of adverse reactions during treatment was observed in the two groups. Kaplan-Meier method was used to compare long-term curative effects of the survival curves of progression-free survival (PFS) and overall survival (OS) between the two groups. ResultsAfter 4 cycles of treatment, the levels of tumor indexes and CD8＋ in two groups were significantly lower than them before treatment (P＜0.05), and Endu combined group was lower than Ectinib group (P＜0.05). The levels of CD3＋, CD4＋, CD4＋/CD8＋ in both groups were higher than them before treatment (P＜0.05), and Endu combined group was higher than Ectinib group (P＜0.05). The OS of the Endu combination group was longer than that of the Ecetinib group (P＜0.05). There was no significant difference in recent efficacy, PFS, and adverse reactions between the two groups of patients (P＞0.05). ConclusionThe second-line treatment regimen of Ecetinib combined with Endu can help improve the overall survival of EGFR mutation positive lung adenocarcinoma patients and is safe. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |